2014
An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation
Chaloupka FJ, Warner KE, Acemoğlu D, Gruber J, Laux F, Max W, Newhouse J, Schelling T, Sindelar J. An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation. Tobacco Control 2014, 24: 112. PMID: 25550419, PMCID: PMC4345832, DOI: 10.1136/tobaccocontrol-2014-052022.Peer-Reviewed Original ResearchConceptsEconomic impact analysisSound economic analysisNet economic benefitsImpact analysisProminent economistsSignificant regulatory actionsEconomic analysisDrug Administration's regulatory authorityNet benefitEconomic benefitsTobacco productsGraphic warning labelsRegulatory authoritiesLabel regulationsCostTobacco product regulationRegulatory actionProduct regulationEconomistsAuthoritiesBenefitsFuture analysesRulesControl ActJurisdictions
2002
Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI
French MT, Salomé HJ, Sindelar JL, McLellan AT. Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI. Health Services Research 2002, 37: 433-455. PMID: 12036002, PMCID: PMC1430361, DOI: 10.1111/1475-6773.031.Peer-Reviewed Original ResearchConceptsDrug Abuse Treatment Cost Analysis ProgramBenefit-cost analysisEconomic evaluationEconomic benefitsFuture economic researchTotal economic benefitTotal economic costFuture economic evaluationsEconomic researchDetailed methodological guidelinesEmpirical applicationConsecutive fiscal yearsSensitivity analysisOutpatient drug-free programsEconomic costsMethodological guidelinesFiscal yearCost dataSubsequent sensitivity analysisDrug-free programsResource useMethodological foundationsBenefitsCostEstimates